The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The S&P 500 ended 2024 with a 25% gain for the year. This marks the second consecutive year of gains exceeding 25% and the third such occurrence in the past four years.

Sales for our core business were up 4% CER when excluding ... securing partnership with Eli Lilly in Alzheimer’s disease or AstraZeneca in chronic diseases. Looking ahead in 2025 and beyond ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...

Learn More » For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45 ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long-term stocks. Ken Fisher is a prominent American billionaire investment analyst ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large cap dividend growth stocks. Investors continue to favor large-cap stocks ...